265 related articles for article (PubMed ID: 24777335)
1. Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain.
Rao PS; Labhart M; Mayhew SL; Thirumala S; Rao US
Tumour Biol; 2014 Jul; 35(7):7267-73. PubMed ID: 24777335
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
[TBL] [Abstract][Full Text] [Related]
3. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.
Kaidar-Person O; Meattini I; Jain P; Bult P; Simone N; Kindts I; Steffens R; Weltens C; Navarria P; Belkacemi Y; Lopez-Guerra J; Livi L; Baumert BG; Vieites B; Limon D; Kurman N; Ko K; Yu JB; Chiang V; Poortmans P; Zagar T
Breast Cancer Res Treat; 2018 Jan; 167(2):479-483. PubMed ID: 28975433
[TBL] [Abstract][Full Text] [Related]
4. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.
Curtit E; Nerich V; Mansi L; Chaigneau L; Cals L; Villanueva C; Bazan F; Montcuquet P; Meneveau N; Perrin S; Algros MP; Pivot X
Oncologist; 2013 Jun; 18(6):667-74. PubMed ID: 23723333
[TBL] [Abstract][Full Text] [Related]
5. Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis.
Jung J; Lee SH; Park M; Youn JH; Shin SH; Gwak HS; Yoo H
J Neurooncol; 2018 Apr; 137(2):295-302. PubMed ID: 29260362
[TBL] [Abstract][Full Text] [Related]
6. HER2 expression is a strong independent predictor of nodal metastasis in breast cancer.
Ahmed AR
J Egypt Natl Canc Inst; 2016 Dec; 28(4):219-227. PubMed ID: 27756653
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
Marotti JD; Collins LC; Hu R; Tamimi RM
Mod Pathol; 2010 Feb; 23(2):197-204. PubMed ID: 19898422
[TBL] [Abstract][Full Text] [Related]
8. Receptor conversion in distant breast cancer metastases.
Hoefnagel LD; van de Vijver MJ; van Slooten HJ; Wesseling P; Wesseling J; Westenend PJ; Bart J; Seldenrijk CA; Nagtegaal ID; Oudejans J; van der Valk P; van der Groep P; de Vries EG; van der Wall E; van Diest PJ
Breast Cancer Res; 2010; 12(5):R75. PubMed ID: 20863372
[TBL] [Abstract][Full Text] [Related]
9. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
[TBL] [Abstract][Full Text] [Related]
10. CORRELATION BETWEEN CLINICAL PATHOLOGY OF LUMINAL B BREAST CANCER AND DETERMINATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND HER2 EXPRESSION COMBINED WITH NUCLEAR MORPHOLOGY.
Yin D; Wang YL; Wang YF; Yang L; Zhang L; Tang C; Xie W; Ma Y
J Biol Regul Homeost Agents; 2015; 29(3):579-87. PubMed ID: 26403396
[TBL] [Abstract][Full Text] [Related]
11. Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material.
Berghuis AMS; van Deurzen CHM; Koffijberg H; Terstappen LWMM; Sleijfer S; IJzerman MJ
Breast Cancer Res Treat; 2019 Jun; 175(2):451-458. PubMed ID: 30756285
[TBL] [Abstract][Full Text] [Related]
12. Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study.
Salagame U; Banks E; O'Connell DL; Egger S; Canfell K
PLoS One; 2018; 13(11):e0205034. PubMed ID: 30403669
[TBL] [Abstract][Full Text] [Related]
13. Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival.
Sperduto PW; Mesko S; Li J; Cagney D; Aizer A; Lin NU; Nesbit E; Kruser TJ; Chan J; Braunstein S; Lee J; Kirkpatrick JP; Breen W; Brown PD; Shi D; Shih HA; Soliman H; Sahgal A; Shanley R; Sperduto W; Lou E; Everett A; Boggs DH; Masucci L; Roberge D; Remick J; Plichta K; Buatti JM; Jain S; Gaspar LE; Wu CC; Wang TJC; Bryant J; Chuong M; Yu J; Chiang V; Nakano T; Aoyama H; Mehta MP
Neuro Oncol; 2020 Sep; 22(9):1359-1367. PubMed ID: 32034917
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients.
Dodson A; Parry S; Ibrahim M; Bartlett JM; Pinder S; Dowsett M; Miller K
J Pathol Clin Res; 2018 Oct; 4(4):262-273. PubMed ID: 30066480
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
[TBL] [Abstract][Full Text] [Related]
16. Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling.
Dai X; Chen A; Bai Z
Sci Rep; 2014 Oct; 4():6566. PubMed ID: 25338681
[TBL] [Abstract][Full Text] [Related]
17. The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer.
Vogel C; Malter W; Morgenstern B; Ludwig S; Vehreschild JJ; Hamacher S; Mallmann P; Kirn V; Thangarajah F
Anticancer Res; 2019 May; 39(5):2647-2659. PubMed ID: 31092464
[TBL] [Abstract][Full Text] [Related]
18. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
[TBL] [Abstract][Full Text] [Related]
19. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
[TBL] [Abstract][Full Text] [Related]
20. Intraocular Metastases Secondary to Breast Carcinoma Correlates With Upregulation of Estrogen and Progesterone Receptor Expression in the Primary Tumor.
Parrozzani R; Frizziero L; Testi I; Miglionico G; Perrini P; Pulze S; Pilotto E; Midena E
Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):3944-8. PubMed ID: 27479811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
